Splice Switching Oligonucleotide | YesPress

Browse all tags

ceo2909 saas2413 ai1729 fintech1453 founder1251 b2b1075 b2b saas887 san francisco823 co-founder816 san-francisco799 y combinator769 startup732 machine learning664 enterprise software625 stanford603 series a590 venture capital577 biotech543 cybersecurity535 healthtech479 new york startup469 ai agents452 enterprise-software446 generative ai437 digital health434 agentic ai393 silicon-valley389 d2c384 silicon valley381 ecommerce378 machine-learning373 startup founder360 california351 entrepreneur350 new york347 edtech342 venture-capital340 climate tech327 newsletter321 mit302 proptech301 robotics294 y-combinator281 san francisco startup278 enterprise ai276 series b271 developer tools264 computer vision255 oncology252 open-source247 series-a243 harvard242 supply chain240 sustainability240 enterprise230 iot230 biotechnology224 compliance224 workflow automation223 telehealth217 founder ceo216 healthcare213 insurtech211 developer-tools210 blockchain209 devops208 medical devices206 series-b206 logistics198 forbes 30 under 30194 llm193 uc berkeley189 author188 generative-ai188 deep tech187 clean energy186 cloud184 web3184 a16z183 drug discovery182 life sciences176 artificial intelligence175 no-code175 manufacturing174 b2c173 payments170 general partner169 healthcare ai169 crm168 serial entrepreneur167 seed funding164 open source162 automation160 podcast160 hardware159 digital transformation158 unicorn158 marketplace152 predictive analytics152 infrastructure151

Often tagged with

biotechnology1 rna-therapeutics1 sso1 copd1 respiratory1 inhaled-therapy1 rage-receptor1 clinical-stage-biotech1 melbourne1 australia1 monash-university1 precision-medicine1 b2b1 drug-development1

Tagged: splice-switching-oligonucleotide

1 result

Sort

Health · Hardware

Atisama Therapeutics

Atisama Therapeutics (formerly Rage Bio) is a Melbourne-based clinical-stage biotech developing precision splice-switching oligonucleotide (SSO) therapies for chronic inflammatory disease. Its lead asset, RB042, is an inhaled RNA drug that targets the RAGE receptor to treat chronic obstructive pulmonary disease (COPD) - a condition affecting hundreds of millions worldwide with few disease-modifying options. Spun out of a collaboration between IP Group Australia, Monash, Murdoch and the University of Western Australia, the company raised a $29M Series A in 2025 and advanced RB042 into Phase 1 clinical trials in 2026.

biotechnology · rna-therapeuticsRead →